MURAT AKYOL1, METE KARA2, AHMET ALACACIOGLU2, LEYLA DEMIR3, HULYA ELLIDOKUZ4, YUKSEL KUCUKZEYBEK2, YASAR YILDIZ2, VEDAT BAYOGLU2, IBRAHIM YILDIZ2, TARIK SALMAN2, UMUT VAROL2, BETUL KUCUKZEYBEK5, UTKU OFLAZOGLU2, HALIL TASKAYNATAN2, ZEHRA GUMUS2, MUSTAFA OKTAY TARHAN4
1Department of Medical Oncology, Manisa State Hospital, Manisa - 2Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir-Turkey - 3Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - 4Institute of Oncology, Dokuz Eylul University, Izmir-Turkey - 5Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Objective: We aimed to investigate changes in body composition, serum asymmetric dimethyl arginine (ADMA) and endothe- lin-1(ET-1) levels before and after adjuvant chemotherapy in early breast cancer patients.
Methods: Seventy-two patients with early breast cancer who admitted to our outpatient clinic were included in the study. Before and after chemotherapy, the anthropometric measurements and bioelectrical impedance analysis with TANITA device, body compositions, serum ADMA and ET-1 levels were recorded.
Results: There was a statistically significant increase of serum ADMA levels ( 112.10±52.24 ng/ml vs. 206.34±128.02 ng/ml, p<0.001) after chemotherapy. On the other hand, the decrease of serum ET- 1 levels was not statistically significant (2.19±6.65 vs.1.68±3.71, p=0.57). ADMA levels was similar in both of the groups treated with anthracycline or anthracycline plus taxane regi- mens. There was no relationship between serum ADMA levels and disease stage/grade, hormone or nodal status. The changes in body composition and antropometric measurements were not statistically significant.
Conclusion: The increased serum levels of ADMA could be caused by the oxidative stress, apoptosis and endothelial dysfunc- tion secondary to chemotherapy and the decreased estrogen levels. The decrease in serum ET-1 levels might be due to the inhibition of cell proliferation and angiogenesis due to adjuvant chemotherapy.
ADMA, Endothelin-1, early stage breast cancer, adjuvant chemotherapy